Abstract | INTRODUCTION: AREAS COVERED: This article reviews potential therapies, namely monoclonal antibodies, that may affect the main axis of pathogenesis of IgA nephropathy with a discussion of their potential impact on the outcome of IgAN. PubMed was used to perform the literature search, which included papers on "treatment of IgA nephropathy"combined with " biological therapy", or ' monoclonal antibodies, atacicept, sibeprenlimab, rituximab, felzartamab, narsoplimab, iptacopan' published up to 2023. EXPERT OPINION: The new treatment options are aimed at the immunopathogenesis of IgAN, including depletion or modulation of Gd-IgA1 producing B cells, plasma cells, alternate or lectin pathway of complement. Monoclonal antibodies may target both B cells and T cells and also the factors needed for their activation and survival, e.g. BAFF or APRIL.
|
Authors | Dita Maixnerova, Vladimir Tesar |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 23
Issue 5
Pg. 419-427
(05 2023)
ISSN: 1744-7682 [Electronic] England |
PMID | 37183663
(Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
|
Chemical References |
- galactosyl-deficient IgA1
- Antibodies, Monoclonal
- Antigen-Antibody Complex
- Immunoglobulin A
- Galactose
|
Topics |
- Humans
- Glomerulonephritis, IGA
(drug therapy)
- Antibodies, Monoclonal
(therapeutic use)
- Antigen-Antibody Complex
- Immunoglobulin A
(metabolism)
- Galactose
(metabolism)
|